Literature DB >> 26053896

Stage I mycosis fungoides: frequent association with a favourable prognosis but disease progression and disease-specific mortality may occur.

A G Wernham1, F Shah1, R Amel-Kashipaz2, M Cobbold3, J Scarisbrick1.   

Abstract

Entities:  

Mesh:

Year:  2015        PMID: 26053896     DOI: 10.1111/bjd.13939

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  5 in total

1.  Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study.

Authors:  P Quaglino; H M Prince; R Cowan; M Vermeer; E Papadavid; M Bagot; O Servitjie; E Berti; E Guenova; R Stadler; C Querfeld; A M Busschots; E Hodak; A Patsatsi; J Sanches; M Maule; J Yoo; M Kevin; P Fava; S Ribero; L Zocchi; M Rubatto; M T Fierro; U Wehkamp; M Marshalko; C Mitteldorf; O Akilov; P Ortiz-Romero; T Estrach; L Vakeva; P A Enz; M Wobser; M Bayne; C Jonak; M Rubeta; A Forbes; A Bates; M Battistella; R Amel-Kashipaz; B Vydianath; A Combalia; E Georgiou; E Hauben; E K Hong; M Jost; R Knobler; I Amitay-Laish; D Miyashiro; J Cury-Martins; X Martinez; C Muniesa; H Prag-Naveh; A Stratigos; V Nikolaou; K Quint; C Ram-Wolff; K Rieger; R Stranzenbach; Á Szepesi; S Alberti-Violetti; E Felicity; L Cerroni; W Kempf; S Whittaker; R Willemze; Y Kim; J J Scarisbrick
Journal:  Br J Dermatol       Date:  2021-02-18       Impact factor: 9.302

2.  Evaluation of the Cutaneous Lymphoma International Prognostic Index in patients with early stage mycosis fungoides.

Authors:  Gustavo Moreira Amorim; João Paulo Niemeyer Corbellini; Danielle Carvalho Quintella; Tullia Cuzzi; Márcia Ramos-E-Silva
Journal:  An Bras Dermatol       Date:  2018 Sep-Oct       Impact factor: 1.896

3.  Clinical and epidemiological profile of patients with early stage mycosis fungoides.

Authors:  Gustavo Moreira Amorim; João Paulo Niemeyer-Corbellini; Danielle Carvalho Quintella; Tullia Cuzzi; Márcia Ramos-E-Silva
Journal:  An Bras Dermatol       Date:  2018 Jul-Aug       Impact factor: 1.896

4.  Ruxolitinib with resminostat exert synergistic antitumor effects in Cutaneous T-cell Lymphoma.

Authors:  Fani Karagianni; Christina Piperi; Vassiliki Mpakou; Aris Spathis; Periklis G Foukas; Maria Dalamaga; Vasiliki Pappa; Evangelia Papadavid
Journal:  PLoS One       Date:  2021-03-11       Impact factor: 3.240

5.  Management of primary cutaneous lymphoma patients during COVID-19 pandemic: EORTC CLTF guidelines.

Authors:  E Papadavid; J Scarisbrick; P Ortiz Romero; P Guaglino; M Vermeer; R Knobler; R Stadler; M Bagot
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-07-07       Impact factor: 9.228

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.